Cochrane · systematic review · CD009411
High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma
Rancea, M, Monsef, I, von Tresckow, B, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 40%Very low 0 · 0%Low 0 · 0%Moderate 3 · 60%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma
Population: Patients with refractory/relapsed Hodgkin lymphoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (after 3 years) | HR 0.67 [0.41, 1.07] | 2 studies · 157 participants | Moderate |
Relapse or death (at 3 years) | HR 0.55 [0.35, 0.86] | 2 studies · 157 participants | Moderate |
Treatment‐related mortality ‐ overall analysis (at 3 years) | RR 0.61 [0.16, 2.22] | 2 studies · 157 participants | Moderate |
Adverse events not estimable | no estimate extracted | 1 study · 100 participants | Ungraded |
Quality of life not reported | no estimate extracted | 0 studies · 0 participants | Ungraded |